Tyra Accounts Payable vs Net Debt Analysis

TYRA Stock

USD 10.48 0.33 3.05%

Tyra Biosciences financial indicator trend analysis is much more than just breaking down Tyra Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tyra Biosciences is a good investment. Please check the relationship between Tyra Biosciences Accounts Payable and its Net Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.

Accounts Payable vs Net Debt

Accounts Payable vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tyra Biosciences Accounts Payable account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Tyra Biosciences' Accounts Payable and Net Debt is -0.16. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Debt in the same time period over historical financial statements of Tyra Biosciences, assuming nothing else is changed. The correlation between historical values of Tyra Biosciences' Accounts Payable and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Tyra Biosciences are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Accounts Payable i.e., Tyra Biosciences' Accounts Payable and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.16

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Tyra Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tyra Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Tyra Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tyra Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.The current year's Enterprise Value is expected to grow to about 670.6 M, whereas Selling General Administrative is forecasted to decline to about 12.2 M.

	2022	2024	2025 (projected)
Interest Expense	296K	340.4K	357.4K
Depreciation And Amortization	296K	519K	545.0K

Interest Expense Depreciation And Amortization

Tyra Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Deferred Long Term Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.79	0.57	0.61	0.76	0.98	0.85	-0.48	-0.8	-0.82	0.41	0.82	0.82	0.79	0.82	1.0	0.57	0.14	0.79	0.86	0.42	-0.48	1.0	0.84	1.0	1.0
Short Long Term Debt Total	0.79		0.9	0.87	0.78	0.76	0.94	-0.72	-0.34	-0.98	0.6	0.41	0.99	0.98	0.95	0.78	0.69	0.18	1.0	0.84	0.6	-0.72	0.78	0.94	0.78	0.77
Other Current Liab	0.57	0.9		0.85	0.74	0.5	0.77	-0.83	-0.05	-0.91	0.34	0.13	0.88	0.91	0.82	0.55	0.8	-0.05	0.9	0.55	0.39	-0.83	0.56	0.78	0.56	0.54
Total Current Liabilities	0.61	0.87	0.85		0.61	0.61	0.91	-0.43	-0.07	-0.81	0.67	0.1	0.82	0.8	0.77	0.59	0.65	-0.04	0.87	0.7	0.44	-0.43	0.6	0.92	0.59	0.57
Total Stockholder Equity	0.76	0.78	0.74	0.61		0.7	0.7	-0.73	-0.42	-0.8	0.27	0.48	0.75	0.74	0.63	0.76	0.68	0.12	0.78	0.57	0.42	-0.73	0.75	0.7	0.76	0.75
Net Tangible Assets	0.98	0.76	0.5	0.61	0.7		0.85	-0.35	-0.82	-0.75	0.51	0.84	0.77	0.73	0.78	0.98	0.45	0.08	0.76	0.9	0.37	-0.35	0.99	0.84	0.98	0.98
Property Plant And Equipment Net	0.85	0.94	0.77	0.91	0.7	0.85		-0.48	-0.41	-0.9	0.71	0.44	0.93	0.89	0.9	0.83	0.63	0.19	0.94	0.89	0.61	-0.48	0.83	1.0	0.83	0.82
Current Deferred Revenue	-0.48	-0.72	-0.83	-0.43	-0.73	-0.35	-0.48		0.15	0.8	0.05	-0.25	-0.75	-0.79	-0.69	-0.48	-0.75	-0.14	-0.72	-0.33	-0.38	1.0	-0.47	-0.49	-0.48	-0.48
Net Debt	-0.8	-0.34	-0.05	-0.07	-0.42	-0.82	-0.41	0.15		0.37	-0.16	-0.99	-0.4	-0.36	-0.46	-0.82	-0.07	-0.03	-0.34	-0.66	-0.07	0.15	-0.82	-0.4	-0.81	-0.82
Retained Earnings	-0.82	-0.98	-0.91	-0.81	-0.8	-0.75	-0.9	0.8	0.37		-0.43	-0.44	-0.99	-0.99	-0.95	-0.81	-0.8	-0.21	-0.98	-0.76	-0.6	0.8	-0.8	-0.91	-0.81	-0.8
Accounts Payable	0.41	0.6	0.34	0.67	0.27	0.51	0.71	0.05	-0.16	-0.43		0.17	0.53	0.44	0.51	0.39	-0.04	0.2	0.6	0.77	0.48	0.05	0.39	0.69	0.4	0.38
Cash	0.82	0.41	0.13	0.1	0.48	0.84	0.44	-0.25	-0.99	-0.44	0.17		0.47	0.43	0.52	0.84	0.12	0.05	0.41	0.68	0.1	-0.25	0.84	0.43	0.83	0.85
Non Current Assets Total	0.82	0.99	0.88	0.82	0.75	0.77	0.93	-0.75	-0.4	-0.99	0.53	0.47		0.99	0.98	0.81	0.71	0.2	0.99	0.84	0.59	-0.75	0.81	0.93	0.81	0.8
Non Currrent Assets Other	0.79	0.98	0.91	0.8	0.74	0.73	0.89	-0.79	-0.36	-0.99	0.44	0.43	0.99		0.98	0.78	0.76	0.17	0.98	0.78	0.57	-0.79	0.78	0.9	0.78	0.77
Other Assets	0.82	0.95	0.82	0.77	0.63	0.78	0.9	-0.69	-0.46	-0.95	0.51	0.52	0.98	0.98		0.81	0.65	0.16	0.95	0.86	0.53	-0.69	0.81	0.9	0.81	0.8
Cash And Short Term Investments	1.0	0.78	0.55	0.59	0.76	0.98	0.83	-0.48	-0.82	-0.81	0.39	0.84	0.81	0.78	0.81		0.56	0.13	0.78	0.85	0.4	-0.48	1.0	0.83	1.0	1.0
Common Stock Shares Outstanding	0.57	0.69	0.8	0.65	0.68	0.45	0.63	-0.75	-0.07	-0.8	-0.04	0.12	0.71	0.76	0.65	0.56		0.14	0.69	0.29	0.45	-0.75	0.56	0.66	0.56	0.55
Non Current Liabilities Total	0.14	0.18	-0.05	-0.04	0.12	0.08	0.19	-0.14	-0.03	-0.21	0.2	0.05	0.2	0.17	0.16	0.13	0.14		0.18	0.13	0.88	-0.14	0.09	0.19	0.13	0.14
Capital Lease Obligations	0.79	1.0	0.9	0.87	0.78	0.76	0.94	-0.72	-0.34	-0.98	0.6	0.41	0.99	0.98	0.95	0.78	0.69	0.18		0.84	0.6	-0.72	0.78	0.94	0.78	0.77
Other Current Assets	0.86	0.84	0.55	0.7	0.57	0.9	0.89	-0.33	-0.66	-0.76	0.77	0.68	0.84	0.78	0.86	0.85	0.29	0.13	0.84		0.46	-0.33	0.85	0.88	0.85	0.85
Total Liab	0.42	0.6	0.39	0.44	0.42	0.37	0.61	-0.38	-0.07	-0.6	0.48	0.1	0.59	0.57	0.53	0.4	0.45	0.88	0.6	0.46		-0.38	0.37	0.61	0.41	0.4
Deferred Long Term Liab	-0.48	-0.72	-0.83	-0.43	-0.73	-0.35	-0.48	1.0	0.15	0.8	0.05	-0.25	-0.75	-0.79	-0.69	-0.48	-0.75	-0.14	-0.72	-0.33	-0.38		-0.47	-0.49	-0.48	-0.48
Net Invested Capital	1.0	0.78	0.56	0.6	0.75	0.99	0.83	-0.47	-0.82	-0.8	0.39	0.84	0.81	0.78	0.81	1.0	0.56	0.09	0.78	0.85	0.37	-0.47		0.83	1.0	1.0
Property Plant And Equipment Gross	0.84	0.94	0.78	0.92	0.7	0.84	1.0	-0.49	-0.4	-0.91	0.69	0.43	0.93	0.9	0.9	0.83	0.66	0.19	0.94	0.88	0.61	-0.49	0.83		0.83	0.82
Total Current Assets	1.0	0.78	0.56	0.59	0.76	0.98	0.83	-0.48	-0.81	-0.81	0.4	0.83	0.81	0.78	0.81	1.0	0.56	0.13	0.78	0.85	0.41	-0.48	1.0	0.83		1.0
Net Working Capital	1.0	0.77	0.54	0.57	0.75	0.98	0.82	-0.48	-0.82	-0.8	0.38	0.85	0.8	0.77	0.8	1.0	0.55	0.14	0.77	0.85	0.4	-0.48	1.0	0.82	1.0

Click cells to compare fundamentals

Tyra Biosciences Account Relationship Matchups

Tyra Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.0M	306.7M	266.2M	225.9M	363.6M	216.1M
Short Long Term Debt Total	142K	1.2M	2.6M	6.5M	6.2M	6.5M
Other Current Liab	1.1M	2.6M	4.3M	10.4M	13.6M	14.3M
Total Current Liabilities	1.9M	3.6M	5.7M	15.3M	14.6M	8.5M
Total Stockholder Equity	(13.6M)	301.7M	(95.7M)	204.3M	343.2M	360.3M
Property Plant And Equipment Net	466K	2.1M	3.5M	8.2M	7.7M	4.1M
Net Debt	(15.1M)	(301.0M)	(248.6M)	(51.5M)	(85.7M)	(90.0M)
Retained Earnings	(14.1M)	(40.4M)	(95.7M)	(164.8M)	(251.3M)	(238.7M)
Accounts Payable	664K	599K	1.1M	4.7M	590K	560.5K
Cash	15.2M	302.2M	251.2M	58.0M	92.0M	131.8M
Non Current Assets Total	730K	2.6M	8.9M	14.2M	16.1M	16.9M
Non Currrent Assets Other	21K	555K	4.4M	6.0M	8.4M	8.8M
Cash And Short Term Investments	15.2M	302.2M	251.2M	203.5M	341.4M	204.2M
Liabilities And Stockholders Equity	16.0M	306.7M	(87.3M)	225.9M	363.6M	381.7M
Non Current Liabilities Total	27.8M	1.3M	2.7M	6.3M	5.8M	5.9M
Capital Lease Obligations	142K	1.2M	2.6M	6.5M	6.2M	6.5M
Other Current Assets	57K	3.8M	6.1M	8.2M	4.0M	4.1M
Total Liab	29.6M	5.0M	8.4M	21.6M	20.4M	16.5M
Net Invested Capital	(13.6M)	301.7M	257.8M	204.3M	343.2M	199.6M
Property Plant And Equipment Gross	509K	2.1M	4.0M	9.0M	9M	4.6M
Total Current Assets	15.3M	304.1M	257.3M	211.7M	347.5M	208.2M
Net Working Capital	13.4M	300.4M	251.6M	196.3M	332.9M	199.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

HLN	Haleon plc
NVDA	NVIDIA
INTC	Intel

When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:

How To Invest In Tyra

Details

Is Tyra Stock a good investment?

Details

What is Tyra Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.

You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.79)

Return On Assets

(0.21)

Return On Equity

(0.31)

The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Tyra Accounts Payable vs Net Debt Analysis

Accounts Payable vs Net Debt

Accounts Payable vs Net Debt Correlation Analysis

Correlation Coefficient

Accounts Payable

Net Debt

Tyra Biosciences fundamental ratios Correlations

Tyra Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tyra Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Non Currrent Assets Other	- 0.99	Retained Earnings
Non Current Assets Total	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Capital Lease Obligations	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Short Long Term Debt Total
Other Assets	- 0.95	Retained Earnings